Akari Therapeutics Plc – American Depositary Share (NASDAQ:AKTX) Sellers Covered 5.97% of Their Shorts

October 2, 2018 - By Hazel Jackson

Akari Therapeutics, Plc (NASDAQ:AKTX) Logo

The stock of Akari Therapeutics Plc – American Depositary Share (NASDAQ:AKTX) registered a decrease of 5.97% in short interest. AKTX’s total short interest was 275,800 shares in October as published by FINRA. Its down 5.97% from 293,300 shares, reported previously. With 37,400 shares average volume, it will take short sellers 7 days to cover their AKTX’s short positions. The short interest to Akari Therapeutics Plc – American Depositary Share’s float is 3.72%.

The stock decreased 2.73% or $0.07 during the last trading session, reaching $2.49. About 422,364 shares traded or 645.41% up from the average. Akari Therapeutics, Plc (NASDAQ:AKTX) has declined 61.71% since October 2, 2017 and is downtrending. It has underperformed by 77.33% the S&P500.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company has market cap of $37.99 million. The Company’s lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. It currently has negative earnings. The firm is based in New York, New York.

More notable recent Akari Therapeutics, Plc (NASDAQ:AKTX) news were published by: Benzinga.com which released: “30 Stocks Moving In Wednesday’s Pre-Market Session” on September 12, 2018, also Globenewswire.com with their article: “Akari Announces Second Quarter 2018 Financial Results and Business Highlights” published on September 27, 2018, Benzinga.com published: “51 Biggest Movers From Yesterday” on September 28, 2018. More interesting news about Akari Therapeutics, Plc (NASDAQ:AKTX) were released by: Streetinsider.com and their article: “Akari Therapeutcis (AKTX) Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients …” published on September 12, 2018 as well as Nasdaq.com‘s news article titled: “Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports …” with publication date: September 30, 2018.

Akari Therapeutics, Plc (NASDAQ:AKTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: